Skip to content
Neuland Laboratories logo

Neuland Laboratories

NEULANDLAB NSE
₹19,576.00 +152.00 (+0.78%)
P/E
50.46
View as Markdown
MCP
Close 4 Nov 2026 ₹19,576.00 +2,026.00 +11.5% 1Y
Start ₹17,550.00

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
26.50%
Debt to Equity
0.16
EPS (TTM)
₹387.97
Book Value
₹1,460.31
Market Cap
—
P/E (TTM)
50.46
P/B
13.41
ROE
21.20%
Dividend Yield
0.18%
EBITDA
₹605 Cr
52W High
₹24,225.00
52W Low
₹11,500.00
Day Range
₹18,501.00 – ₹19,850.00
Volume
1,48,314

Peer Comparison

Healthcare › Pharmaceuticals

Neuland Laboratories peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Neuland Laboratories (this company)
₹19,576.0050.46₹25,039 Cr13.410.18%21.20%26.50%₹2,372 Cr₹499 Cr
Median 8 companies₹2,048.6044.64₹1,25,337 Cr7.290.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

49 Average

Data confidence 100/100

Category scores

Quality
44
Weak
Returns, margins, earnings quality 22% weight
Valuation
37
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
74
Strong
Solvency, leverage, coverage 9% weight
Momentum
34
Poor
Trend strength, vol-adjusted 12% weight
Ownership
38
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 38.5% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 15.0 times its book value
  • Promoter holding has decreased over last 3 years: -3.35%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish856
OscillatorsNeutral252
Moving AveragesStrong Bearish604

Key readings

RSI (14)
41.18
Neutral
MACD (12,26,9)
−563.43
Bullish
SMA (50)
21,517.28
Bearish
SMA (200)
17,468.12
Bullish

As of

Analyst Rating

Based on 4 analysts
BUY100%

4 of 4 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
4
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+14.77%
5Y+16.64%
3Y+19.31%
1Y+36.97%
TTM+78.35%

Net profit

Net profit growth by window
10Y+29.71%
5Y+35.06%
3Y+30.44%
1Y+40.00%
TTM+181.92%

Operating cash flow

Operating cash flow growth by window
10Y+22.66%
5Y+12.92%
3Y+13.55%
1Y+9.46%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+12.98 pp
5Y+12.98 pp
3Y+5.75 pp
1Y+6.26 pp
TTM+14.58 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹579 Cr
Mar 2018₹527 Cr
Mar 2019₹667 Cr
Mar 2020₹763 Cr
Mar 2021₹937 Cr
Mar 2022₹951 Cr
Mar 2023₹1,191 Cr
Mar 2024₹1,559 Cr
Mar 2025₹1,477 Cr
Mar 2026₹2,023 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹47.00 Cr
Mar 2018₹12.00 Cr
Mar 2019₹16.00 Cr
Mar 2020₹16.00 Cr
Mar 2021₹81.00 Cr
Mar 2022₹64.00 Cr
Mar 2023₹164 Cr
Mar 2024₹300 Cr
Mar 2025₹260 Cr
Mar 2026₹364 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹725 Cr +19.9% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk medium

Neuland Laboratories Ltd trades at ₹19,576 as of 2026-11-04 with a market cap of ₹25,039 Cr and a PE of 50.46x. The company has delivered exceptional profit growth of 39% CAGR over five years and 278% TTM, supported by a healthy ROCE of 23.11% and low debt-to-equity of 0.16, though the stock trades at a significant premium to book value at 13.41x.

Bull Case 8
  • TTM revenue growth of 78% signals a sharp acceleration in the business, well above the 5-year compounded sales growth of 17%
  • TTM profit growth of 278% demonstrates significant operating leverage and margin expansion in the most recent period
  • Five-year compounded profit growth of 39% reflects a sustained earnings trajectory over a meaningful period
  • ROCE of 23.11% indicates efficient capital deployment, comfortably above the cost of capital for most Indian firms
  • Debt-to-equity ratio of just 0.16 provides a strong balance sheet with minimal financial risk and headroom for future capex
  • ROE of 19.42% (with a 3-year average of 20% and last year at 21%) shows consistent and improving return generation for shareholders
  • Ten-year compounded profit growth of 29% and sales growth of 15% demonstrate a long track record of sustained business expansion
  • The stock is currently 19.2% below its 52-week high of ₹24,225, which may provide a more favourable entry zone compared to recent peaks
Bear Case 7
  • PE ratio of 50.46x is elevated relative to broader market averages, pricing in substantial future growth that must be sustained to justify the valuation
  • Price-to-book ratio of 13.41x (15.0x on certain metrics) implies the stock trades at a steep premium to its net asset value
  • Promoter holding has declined by 3.35% over the last three years, which may signal reduced insider confidence or dilution
  • Dividend yield of just 0.18% offers negligible income return, meaning nearly all investor return depends on capital appreciation
  • The stock has risen 70% from its 52-week low of ₹11,500 to ₹19,576, embedding a significant amount of optimism into the current price
  • Five-year stock CAGR of 71% has far outpaced the five-year profit CAGR of 39%, suggesting valuation re-rating that may not be sustainable
  • TTM profit growth of 278% creates a very high base, making comparable growth in subsequent periods increasingly difficult and raising the risk of earnings deceleration

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Neuland Labs delivered a weak Q2FY27 with profit down 47% and margins contracting sharply, though results still beat consensus estimates. The US FDA's Unit 3 inspection closure removes a regulatory overhang. Management's ~20% medium-term growth guidance backed by CMS scale-up remains intact, but quarterly lumpiness in CMS orders will keep near-term earnings volatile. The structural thesis is positive, though investors should expect uneven quarters ahead.

Headwinds 2
  • Net profit drops 47% YoY Nov 4

    Q2FY27 net profit fell 47% YoY with EBITDA declining 37% YoY. EBITDA margin contracted 856 bps YoY to 21.7% due to operating deleverage.

  • Lumpy CMS order flow Nov 4

    Management flagged uneven quarterly performance ahead due to inherent lumpiness of CMS orders, creating near-term earnings visibility risk.

Positives 2
  • FDA Unit 3 inspection closure Oct 14

    US FDA signalled closure of its inspection of Neuland Labs' Unit 3 facility, marking a key regulatory milestone for the API manufacturer in the US regulated market.

  • ~20% medium-term growth guided Nov 4

    Management reiterated medium-term revenue growth aspiration of around 20%, supported by ongoing CMS business scale-up.

Quarterly Results

₹ Cr
NEULANDLAB quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
363
418
393
385
440
311
398
328
293
514
440
776
642
450
Expenses
266
280
272
278
316
249
311
277
258
359
363
469
419
352
Operating Profit
97
137
121
107
123
62
87
51
34
156
77
307
223
98
OPM %
27%
33%
31%
28%
28%
20%
22%
16%
12%
30%
18%
40%
35%
22%
Other Income
2
3
2
5
25
4
60
7
8
2
8
12
8
7
Interest
2
4
4
4
3
1
2
2
5
5
7
7
7
7
Depreciation
14
15
15
16
16
16
16
17
20
23
24
25
27
29
PBT
83
122
104
92
130
49
128
39
18
129
54
287
198
69
Tax %
26%
27%
22%
27%
25%
34%
20%
29%
21%
25%
26%
26%
25%
25%
Net Profit
62
89
81
68
98
33
102
28
14
97
41
213
148
52
EPS (₹)
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.68
10.83
75.49
31.62
166
115
—

Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
NEULANDLAB profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
469
510
579
527
667
763
937
951
1,191
1,559
1,477
2,023
2,372
Expenses
402
430
472
477
608
661
790
807
918
1,096
1,146
1,443
1,609
Operating Profit
67
80
106
51
58
102
147
144
273
463
331
580
763
OPM %
14%
16%
18%
10%
9%
13%
16%
15%
23%
30%
22%
29%
32%
Other Income
0
2
1
4
3
4
16
0
9
12
90
25
31
Interest
27
24
21
19
16
22
18
14
13
14
8
24
26
Depreciation
15
16
19
22
26
31
40
49
53
60
66
92
98
PBT
25
42
67
14
20
53
105
82
216
401
346
489
669
Tax %
36%
36%
30%
13%
19%
69%
23%
22%
24%
25%
25%
26%
—
Net Profit
16
27
47
12
16
16
81
64
164
300
260
364
498
EPS (₹)
17.96
30.75
52.74
13.57
12.81
12.63
62.85
49.74
127
234
203
284
388
Div. Payout %
8%
7%
0%
0%
0%
16%
8%
10%
8%
6%
6%
12%
—

Balance Sheet

₹ Cr
NEULANDLAB balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
9
9
13
13
13
13
13
13
13
13
Reserves
152
178
537
549
686
697
774
828
981
1,270
1,512
1,862
Borrowings
188
182
192
319
231
264
182
241
128
95
157
301
Other Liabilities
162
155
148
194
200
257
356
302
457
454
498
754
Total Liabilities
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930
Fixed Assets
123
139
466
475
542
653
716
767
758
824
955
1,177
CWIP
41
40
20
126
104
24
17
20
41
46
48
211
Investments
7
7
8
8
8
8
7
4
1
1
109
2
Other Assets
340
337
393
463
476
547
585
592
781
962
1,068
1,541
Total Assets
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930

Cash Flow

₹ Cr
NEULANDLAB cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
13
45
39
11
70
57
189
60
237
261
317
347
Investing
−14
−20
−42
−116
−77
−49
−84
−95
−61
−150
−298
−423
Financing
1
−24
0
105
12
−5
−114
38
−136
−69
25
21
Net Cash Flow
0
1
−4
0
5
3
−9
3
40
42
44
−55
Free Cash Flow
−1
26
−2
−121
7
9
84
−37
173
119
112
−50
CFO/OP
33
70
52
28
128
61
132
56
103
81
119
78

Ratios

NEULANDLAB financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
100
85
114
134
90
91
85
90
111
87
78
98
Inventory Days
170
182
186
266
191
209
205
227
211
220
238
245
Days Payable
167
121
118
189
118
110
126
100
129
121
156
129
Cash Conversion Cycle
103
147
182
211
162
190
164
216
193
187
160
214
Working Capital Days
11
26
44
38
138
137
60
74
81
88
76
75
ROCE %
16%
18%
16%
4%
4%
8%
11%
10%
21%
33%
19%
26%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Neuland Laboratories insights

71 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 32.26%
  • Public 22.47%
  • FIIs 21.93%
  • DIIs 16.26%
  • Others 7.08%

2.32% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Neuland Laboratories

What does Neuland Laboratories Ltd do?
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Where is Neuland Laboratories Ltd (NEULANDLAB) listed?
Neuland Laboratories Ltd trades as NEULANDLAB on the NSE and under code 524558 on the BSE.
Which sector does Neuland Laboratories Ltd belong to?
Neuland Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Neuland Laboratories Ltd?
Neuland Laboratories Ltd trades at a PE ratio of 50.46 as of 4 Nov 2026, on earnings per share of ₹387.97, against a book value of ₹1,460.31 per share.
What is the 52-week high and low of Neuland Laboratories Ltd?
Over the last 52 weeks Neuland Laboratories Ltd has traded between ₹11,500 and ₹24,225 as of 4 Nov 2026.
Does Neuland Laboratories Ltd pay dividends?
Neuland Laboratories Ltd has a dividend yield of 0.18%.
What is the Return on Equity (ROE) of Neuland Laboratories Ltd?
Neuland Laboratories Ltd reported a return on equity of 21.20%. Its debt-to-equity ratio is 0.16.

Company Information

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.

Website neulandlabs.com
CEO Dr. Davuluri Rama Mohan Rao
Employees 1,794
Listed 13 Oct 2008
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEULANDLAB.md for Neuland Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month